Black Diamond Therapeutics Announces FDA Notified Co. That It May Only Enroll Up To 50 Patients In Phase 2 of BDTX-189; Co. Announces 'The Company has initiated the GLP toxicology studies and does not anticipate any delays to its clinical trial timelines'